Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Of Patents And Production: Industry-White House Row Over Vaccine Exports Highlights Policy Divide

Executive Summary

BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.

You may also be interested in...



Quick BIO CEO Departure Raises Questions About Direction For Next Leadership Pick

Michelle McMurry-Heath brought a science and regulatory background to the top post of the industry trade group in contrast to the political and lobbying focused careers of her predecessors. Her eventual successor may offer hints as to whether BIO thought that was a successful leadership strategy.

What Vexed Top Global Biopharmaceutical Executives About COVID-19 Response

Pfizer, Eli Lilly and Roche bosses say no country was perfect in its response to the coronavirus pandemic and there are lessons to be learnt.

Biden’s Vaccine Donation Plan Emphasizes American Production, Not IP Waivers

President announces ‘new effort’ to work with pharmaceutical companies, other nations to increase supply. Details remain in short supply, but Biden says plan will increase domestic production capacity to prepare ‘the next crises.’

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel